Aragen Life Sciences is increasing investments in complex drug modalities and manufacturing. The company plans to add significant small-molecule CDMO capacity and a biologics facility. Aragen aims to transition from a molecules company to a medicines company through expansion. This strategic move aligns with global drugmakers seeking supply chain alternatives outside China. The firm is also developing its own intellectual property around antibody-drug conjugates.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.